共同药业(300966) - 2025 Q4 - 年度业绩预告

Financial Performance - Hubei Gongtong Pharmaceutical Co., Ltd. expects a net loss attributable to shareholders of between 58 million and 75 million yuan for the fiscal year 2025[1]. Gross Margin and Costs - The decline in gross margin compared to the same period last year is attributed to slight decreases in market prices of certain products and higher unit costs due to new projects not fully releasing capacity[2]. Research and Development - Increased R&D investment has led to a rise in R&D expenses[2]. Interest Expenses - Interest expenses have increased due to the cessation of capitalization of interest on convertible bonds and project-specific loans after the fundraising projects were completed[2].